An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

April 30, 2015

Conditions
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions
BIOLOGICAL

Ipilimumab

OTHER

Best Supportive care (BSC)

Trial Locations (36)

100

Local Institution, Taipei

112

Local Institution, Taipei

10016

Nyu Clinical Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

20133

Local Institution, Milan

28040

Local Institution, Madrid

28050

Local Institution, Madrid

31059

Local Institution, Toulouse

33140

Mount Sinai Medical Center, Miami Beach

34295

Local Institution, Montpellier

35042

Local Institution, Rennes

35128

Local Institution, Padua

50134

Local Institution, Florence

55131

Local Institution, Mainz

56126

Local Institution, Pisa

77030

The University Of Texas Md Anderson Cancer Center, Houston

169610

Local Institution, Singapore

308433

Local Institution, Singapore

3620806

Local Institution, Kitaadachi-gun

3840301

Local Institution, Saku-shi

4648681

Local Institution, Nagoya

5898511

Local Institution, Osaka-sayama-shi

06202

Local Institution, Nice

Unknown

Local Institution, Hong Kong

00189

Local Institution, Roma

40-635

Local Institution, Katowice

31-501

Local Institution, Krakow

93-513

Local Institution, Lodz

10-513

Local Institution, Olsztyn

115 478

Local Institution, Moscow

431-796

Local Institution, Gyeonggi-do

463-707

Local Institution, Gyeonggi-do

110-774

Local Institution, Seoul

135-705

Local Institution, Seoul

135-720

Local Institution, Seoul

08035

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY